June 8, 2015—The White House Office of Management and Budget has finished reviewing a proposed 340B program regulation to impose civil monetary sanctions on drugmakers that intentionally overcharge safety-net healthcare providers for 340B-discounted drugs.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)